Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : MaaT013,Vancomycin Hydrochloride
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : EIB
Deal Size : Undisclosed
Deal Type : Financing
MaaT Pharma Secures €37.5 Million Loan From European Investment Bank (EIB)
Details : The financing aims to advance the clinical development of Xervyteg (MaaT013), which is being evaluated in the late-stage clinical trial studies for the treatment of Graft-versus-Host Disease.
Product Name : Xervyteg
Product Type : Protein
Upfront Cash : Undisclosed
July 28, 2025
Lead Product(s) : MaaT013,Vancomycin Hydrochloride
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : EIB
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : MaaT013,Vancomycin Hydrochloride
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Clinigen Group
Deal Size : $33.6 million
Deal Type : Licensing Agreement
MaaT Pharma Announces Exclusive Commercialization Partnership With Clinigen for Xervyteg
Details : MaaT and Clinigen signed exclusive long-term licensing agreement and commercial supply agreement for Xervyteg (MaaT013), its first in class treatment proposed for patients with acute GVHD.
Product Name : Xervyteg
Product Type : Protein
Upfront Cash : $12.4 million
July 02, 2025
Lead Product(s) : MaaT013,Vancomycin Hydrochloride
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Clinigen Group
Deal Size : $33.6 million
Deal Type : Licensing Agreement
Lead Product(s) : Vancomycin Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Glenmark USA Launches Vancomycin Hydrochloride Injection in Multiple Doses
Details : Vancomycin Hydrochloride for Injection is a glycopeptide antibacterial indicated in adult and pediatric patients (neonates and older) for the treatment of septicemia.
Product Name : Vancomycin Hydrochloride for Injection
Product Type : Antibiotic
Upfront Cash : Inapplicable
April 01, 2025
Lead Product(s) : Vancomycin Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vancomycin Hydrochloride
Therapeutic Area : Dermatology
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Expanded Access Program (EAP) STIMULAN VG
Details : Vancomycin is a Antibiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Pressure Ulcer.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
February 05, 2025
Lead Product(s) : Vancomycin Hydrochloride
Therapeutic Area : Dermatology
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SER-155,Vancomycin Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Seres Therapeutics Announces New Biomarker Results from SER-155 Phase 1b
Details : SER-155 decreases the colonization and abundance of bacterial pathogens, and to enhance epithelial barrier integrity in the GI tract, decreasing the incidence of bloodstream infections.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Inapplicable
January 09, 2025
Lead Product(s) : SER-155,Vancomycin Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SER-155,Vancomycin Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Seres Receives Breakthrough Therapy Designation for SER-155 in Stem Cell Transplants
Details : SER-155 decreases the colonization and abundance of bacterial pathogens, and to enhance epithelial barrier integrity in the GI tract, decreasing the incidence of bloodstream infections.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Inapplicable
December 09, 2024
Lead Product(s) : SER-155,Vancomycin Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SER-155,Vancomycin Hydrochloride
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Seres Therapeutics Shares SER-155 Phase 1b Results in Patients Undergoing allo-HSCT
Details : SER-155 decreases the colonization and abundance of bacterial pathogens, and to enhance epithelial barrier integrity in the GI tract, decreasing the incidence of bloodstream infections.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Inapplicable
September 12, 2024
Lead Product(s) : SER-155,Vancomycin Hydrochloride
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vancomycin Hydrochloride
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase IV
Sponsor : Health Sciences Centre Winnipeg
Deal Size : Inapplicable
Deal Type : Inapplicable
Powdered Intrawound Vancomycin in Open Fractures Trial
Details : Vancomycin is a Antibiotic drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Fractures, Open.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
July 17, 2024
Lead Product(s) : Vancomycin Hydrochloride
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase IV
Sponsor : Health Sciences Centre Winnipeg
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vancomycin Hydrochloride
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : MCRA
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Vancomycin is a Antibiotic drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pressure Ulcer.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
February 28, 2024
Lead Product(s) : Vancomycin Hydrochloride
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : MCRA
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VE202,Vancomycin Hydrochloride
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Vedanta Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VE202 is a first-in-class, orally administered, investigational live biotherapeutic product (LBP) consortium consisting of 16 strains of bacteria, which is investigated for the treatment of ulcerative colitis.
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
October 04, 2023
Lead Product(s) : VE202,Vancomycin Hydrochloride
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Vedanta Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable